Lasa Suprergenerics Ltd is demerged company from Omkar Speciality Chemicals which got listed recently. Lasa is leader in Veterinary API products, Animal feed ingredients.
Company has alliances with leading Indian and global animal health care conglomerates, and uses Good Manufacturing Practice (GMP) and world-class technologies in its operations. It has manufacturing units in Mahad and Chiplun with a total capacity of 4300 tons per annum . Majority of products are used in making deworming drugs for dairy animals such as cows, buffalos, camel, goats and pet cats, dogs which is expected to rise very fast looking at existing trends.
Financials :
Since it is newly listed company after demerger and as per the latest 6 months financial performance it achieved Rs 125 crores of turnover with half year EPS of Rs 6.8 on equity base of 22.68 crores. Management is confident of growing at 20-22% growth rate and maintaining and improving the net profit margin.
Looking at last six months performance it can easily achieve turn over of approx. 240 crores in FY 17-18 and deliver EPS of 13-14.
Stock is available at attractive PE multiple of 10 based upon CMP of Rs 141. Company has very little competition in its product and it has already filed 7 products for patent. Company seems to be confident of 20-22% growth for next 3 years.
In lieu of above stock can easily start enjoying PE multiple of 15-16 and based upon expected EPS of of 14-15 stock can easily achieve given target of 200 plus in one year. long term investor can hold it for 1-3 years for even better returns.
Company has alliances with leading Indian and global animal health care conglomerates, and uses Good Manufacturing Practice (GMP) and world-class technologies in its operations. It has manufacturing units in Mahad and Chiplun with a total capacity of 4300 tons per annum . Majority of products are used in making deworming drugs for dairy animals such as cows, buffalos, camel, goats and pet cats, dogs which is expected to rise very fast looking at existing trends.
Financials :
Since it is newly listed company after demerger and as per the latest 6 months financial performance it achieved Rs 125 crores of turnover with half year EPS of Rs 6.8 on equity base of 22.68 crores. Management is confident of growing at 20-22% growth rate and maintaining and improving the net profit margin.
Looking at last six months performance it can easily achieve turn over of approx. 240 crores in FY 17-18 and deliver EPS of 13-14.
Stock is available at attractive PE multiple of 10 based upon CMP of Rs 141. Company has very little competition in its product and it has already filed 7 products for patent. Company seems to be confident of 20-22% growth for next 3 years.
In lieu of above stock can easily start enjoying PE multiple of 15-16 and based upon expected EPS of of 14-15 stock can easily achieve given target of 200 plus in one year. long term investor can hold it for 1-3 years for even better returns.
thanks Sir, its really a good stock to own
ReplyDeleteSuperb call. Amazing that people not recognising the genius
ReplyDeleteMukesh ji, stock lingering around 120 due to promoter group corporate governance issue... any thoughts ?
ReplyDeletealready touched 210 post rccomendation and fell down due to thia issue...i guess..kindly guide sir
ReplyDelete